<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">

<channel>
<image>
<title>freepatentsonline.com</title>
<width>141</width>
<height>131</height>
<link>http://www.freepatentsonline.com/index.html</link>
<url>http://www.freepatentsonline.com/images/logo.gif</url>
</image>

<title>freepatentsonline.com: Drug, bio-affecting and body treating compositions</title>
<link>http://www.freepatentsonline.com/result.html?query_txt=ccl/514%20and%20isd/11/03/2009&amp;uspat=on</link>
<description>USPTO Class 514 Drug, bio-affecting and body treating compositions</description>
<language>en-us</language>
<lastBuildDate>Thu, 05 Nov 2009 03:35:24 EST</lastBuildDate>

<item>
<title><![CDATA[Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists]]></title>
<link>http://www.freepatentsonline.com/7612056.html</link>
<description><![CDATA[This invention concerns substituted diaza-spiro-[4.5]-decane derivatives having neurokinin antagonistic activity, in particular NK 1  antagonistic activity, a combined NK 1 /NK 2  antagonistic activity, a combined NK 1 /NK 3  antagonistic activity and a combined NK 1 /NK 2 /NK 3  antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence.  The compounds according to the invention can be represented by general Formula (I) 
 
and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim  1.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Supramolecular complexes as photoactivated DNA cleavage agents]]></title>
<link>http://www.freepatentsonline.com/7612057.html</link>
<description><![CDATA[The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging π-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated. The complexes function when irradiated with low energy visible light with or without molecular oxygen.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Peptoid compounds]]></title>
<link>http://www.freepatentsonline.com/7612036.html</link>
<description><![CDATA[The invention relates to new peptoid compounds of formula (I), as well as their use in the treatment of bacterial infections, such as those caused by vancomycin resistant microorganisms, and to compositions thereof.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline]]></title>
<link>http://www.freepatentsonline.com/7612096.html</link>
<description><![CDATA[Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Treatment and inhibition of disease conditions using flexible heteroarotinoids]]></title>
<link>http://www.freepatentsonline.com/7612107.html</link>
<description><![CDATA[The present invention contemplates methods of treating, reducing, inhibiting or preventing several diseases by the administration of flexible heteroarotinoids. Among the diseases or conditions which can benefit from treatment with flexible heteroarotinoids as described herein are, (1) cancers and other diseases that involve abnormal differentiation, (2) diabetes, (3) hemophilia, (4) liver disease, (5) diseases involving human aldehyde dehydrogenase 2, (6) polycystic kidney disease, (7) lysosomal storage diseases, (8) high cholesterol, (9) obesity, (10) high triglycerides, (11) glycoprotein metabolism diseases, and (12) diseases involving abnormal angiogenesis.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes]]></title>
<link>http://www.freepatentsonline.com/7612109.html</link>
<description><![CDATA[Water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, process for its production and medicament for the treatment and prophylaxis of iron deficiency conditions.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Melanoma antigens and their use in diagnostic and therapeutic methods]]></title>
<link>http://www.freepatentsonline.com/7612044.html</link>
<description><![CDATA[The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Esterified fatty acid composition]]></title>
<link>http://www.freepatentsonline.com/7612111.html</link>
<description><![CDATA[The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions of the present invention have the advantage of increased stability, a reduction of arachidonic acid in cells, a reduction in eicosanoid production and enhanced cell regulation and communication. Also disclosed are methods for using the compositions for treatment and prevention.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Prostaglandin EP<sub>4 </sub>antagonists]]></title>
<link>http://www.freepatentsonline.com/7612082.html</link>
<description><![CDATA[Disclosed herein are methods and compositions related to compound 1 or compound 2  
 
or pharmaceutically acceptable salts, or prodrugs thereof, which are antagonists of a prostaglandin EP 4  receptor, or are prostaglandin EP 4  antagonists.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions of treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination therapy]]></title>
<link>http://www.freepatentsonline.com/7612093.html</link>
<description><![CDATA[Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Utilization of dialkylfumarates]]></title>
<link>http://www.freepatentsonline.com/7612110.html</link>
<description><![CDATA[The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis]]></title>
<link>http://www.freepatentsonline.com/7612050.html</link>
<description><![CDATA[A bisphosphonate for the treatment of osteonecrosis and/or osteonecrosis dissecans. The drug may further he used to prevent the onset of osteonecrosis and/or osetonecrosis dissecans and any complications associated with both diseases.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Combinations comprising epothilones and pharmaceutical uses thereof]]></title>
<link>http://www.freepatentsonline.com/7612052.html</link>
<description><![CDATA[The invention relates to a combination which comprises (a) a bisphosphonate, a platinum compound or a vasculostatic compound and (b) an epothilone derivative of formula I  
 
wherein A represents O or NR N , wherein R N  is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition, a commercial package or product comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease and to a method of treatment of a warm-blooded animal.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Composition containing benzamidine derivative and method for stabilizing benzamidine derivative]]></title>
<link>http://www.freepatentsonline.com/7612066.html</link>
<description><![CDATA[The present invention provides a composition containing a benzamidine derivative that does not decompose even when placed under humidification conditions and a method for stabilizing a benzamidine derivative. According to the present invention, decomposition reaction of a benzamidine derivative can be suppressed by adding to a benzamidine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, at least one type of electrolyte selected from the group consisting of halide salts of alkaline metal or alkaline earth metal and alkaline metal salts or alkaline earth metal salts of perchloric acid.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compositions and methods employing aminopterin]]></title>
<link>http://www.freepatentsonline.com/7612071.html</link>
<description><![CDATA[The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring]]></title>
<link>http://www.freepatentsonline.com/7612073.html</link>
<description><![CDATA[The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[GTPase inhibitors and use thereof for controlling platelet hyperactivity]]></title>
<link>http://www.freepatentsonline.com/7612080.html</link>
<description><![CDATA[The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Urea substituted imidazoquinoline ethers]]></title>
<link>http://www.freepatentsonline.com/7612083.html</link>
<description><![CDATA[Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Heterocyclic compounds as inhibitors of beta-lactamases]]></title>
<link>http://www.freepatentsonline.com/7612087.html</link>
<description><![CDATA[This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in combination with a β-lactamine antibiotic wherein said combination can be administered separately, together or spaced out over time. Pharmaceutical compositions comprising a compound of formula (I), or a combination of a compound of formula (I) and a therapeutically effective amount of a β-lactamine antibiotic, and a pharmaceutically acceptable carrier are also disclosed and claimed.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Aqueous pharmaceutical compositions]]></title>
<link>http://www.freepatentsonline.com/7612115.html</link>
<description><![CDATA[The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent.  The present invention relates to an antibacterial aqueous pharmaceutical composition
 
     which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Compounds, compositions and methods for controlling biofilms and bacterial infections]]></title>
<link>http://www.freepatentsonline.com/7612045.html</link>
<description><![CDATA[The present invention provides compounds and compositions useful for controlling bacterial biofilms as well as for controlling and/or preventing bacterial infections. The compounds of the invention are pentacyclic acid triterpenes. Methods for controlling biofilms and for controlling and/or preventing bacterial infections are also disclosed.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Abnormal cannabidiols as agents for lowering intraocular pressure]]></title>
<link>http://www.freepatentsonline.com/7612101.html</link>
<description><![CDATA[The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I  
 
wherein Y, Q, Z, R, R 1  and R 2  are as defined in the specification.
 The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Pleuromutilin derivatives as antimicrobials]]></title>
<link>http://www.freepatentsonline.com/7612103.html</link>
<description><![CDATA[Compounds of formula  
 
wherein
 R 1  and R 1 ′ are hydrogen or deuterium, R 2 , R 3  and R 4  are hydrogen or deuterium, R 5  is the residue of an amino acid, X is S or N-ALK, 
 
 
is piperidinyl or tetrahydropyridinyl,
 ALK is (C 1-4 )alkyl, and R 6  is hydrogen, hydroxy or (C 2-12 )acyloxy,
 
and their use as antimicrobials.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Tramadol-based medicament]]></title>
<link>http://www.freepatentsonline.com/7611730.html</link>
<description><![CDATA[The invention relates to a medicament containing the racemate of tramadol in a retarded form and the (+)-enantiomer of tramadol in a non-retarded form.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Lefty polypeptides and derivatives thereof]]></title>
<link>http://www.freepatentsonline.com/7612040.html</link>
<description><![CDATA[The disclosure relates to Lefty derivatives and the uses of Lefty polypeptides as antagonists of the function of certain ligands such as Nodal, GDF-8 (Myostatin), and GDF-11. These derivatives may be fused to other functional heterologous proteins such as IgG, especially the Fc portion of IgG. According to the disclosure, Lefty polypeptides are useful in the treatment of a variety of disorders, including, for example, neuronal diseases, muscle and bone conditions, and metabolic disorders.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of reducing or inhibiting ObR signaling using a leptin antagonist consisting of SEQ id No: 2]]></title>
<link>http://www.freepatentsonline.com/7612043.html</link>
<description><![CDATA[Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling in the leptin-responsive cell. Administration of the peptide effectively prevents embryo implantation in a mammal to which the peptide has been administered. Also disclosed herein is a method for identifying a peptide antagonist of ObR, wherein the peptide comprises a leptin sequence.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Quick water-dissolving film containing cosmetic, aromatic, pharmaceutical or food substances]]></title>
<link>http://www.freepatentsonline.com/7612048.html</link>
<description><![CDATA[Film with high solubility in water, comprising a starch, a cellulose and a cosmetic, aromatic, pharmaceutical and/or food substance in a quantity exceeding 10% on the total film weight.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[7-Substituted fused ring tetracycline compounds]]></title>
<link>http://www.freepatentsonline.com/7612053.html</link>
<description><![CDATA[7-substituted fused ring tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted fused ring tetracycline compounds are described.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof]]></title>
<link>http://www.freepatentsonline.com/7612054.html</link>
<description><![CDATA[The present invention pertains to novel dibenzo[b,f]oxepine-10-carboxamides compound to a process for the preparation of such compounds of formula I, their use as a pharmaceuticals, especially in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, and to pharmaceutical compositions and combinations comprising such compounds of formula I.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Macrocyclic lactams and pharmaceutical use thereof]]></title>
<link>http://www.freepatentsonline.com/7612055.html</link>
<description><![CDATA[The present invention relates to novel macrocyclic compounds of the formula  
 
wherein R 1 , R 2 , R 3 , U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for inhibiting sterol absorption]]></title>
<link>http://www.freepatentsonline.com/7612058.html</link>
<description><![CDATA[The present invention provides compositions, therapeutic combinations and methods including: (a) at least one peroxisome proliferator-activated receptor activator; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Piperazine compounds]]></title>
<link>http://www.freepatentsonline.com/7612061.html</link>
<description><![CDATA[A compound selected from those of formula (I):  
 
wherein:
 
     R 1 , R 2 , R 3  and R 4 , which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH 2 ) m —, —OCH 2 — and —NR 5 —, wherein m represents 1 or 2, and R 5  is as defined in the description, Y represents an oxygen atom or a group selected from NR 7  and CHR 8 , wherein R 7  and R 8  are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group,
 
its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid.
 
     
 Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK 1  antagonist.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Pyrrolobenzodiazepines]]></title>
<link>http://www.freepatentsonline.com/7612062.html</link>
<description><![CDATA[Compounds of the formula: (I) or solvate thereof, wherein: R 2  is an optionally substituted C 5-20  aryl group; R 6  and R 9  are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo; where R and R′ are independently selected from optionally substituted C 1-12  alkyl, C 3-20  heterocyclyl and C 5-20  aryl groups; R 7  is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NHRR′, nitro, Me 3 Sn and halo; R″ is a C 3-12  alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings; X is selected from O, S, or NH; z is 2 or 3; M is a monovalent pharmaceutically acceptable cation; R 2 ′, R 6 ′, R 7 ′, R 9 ′, X′ and M′ are selected from the same groups as R 2 , R 6 , R 7 , R 9 , X and M respectively, or M and M′ may together represent a divalent pharmaceutically acceptable cation.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor]]></title>
<link>http://www.freepatentsonline.com/7612072.html</link>
<description><![CDATA[The present invention relates to a novel amorphous form of the dihydrogenphosphate salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural formula I as well as a process for its preparation, pharmaceutical compositions containing this novel form, and methods of use of the novel form and pharmaceutical compositions for the treatment of diabetes, obesity, and high blood pressure.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Amine derivatives for the treatment of asthma and COPD]]></title>
<link>http://www.freepatentsonline.com/7612084.html</link>
<description><![CDATA[The invention relates to compounds of formula (1)  
 
and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[JNK inhibitors]]></title>
<link>http://www.freepatentsonline.com/7612086.html</link>
<description><![CDATA[The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Heterocyclic compounds and their use as aldosterone synthase inhibitors]]></title>
<link>http://www.freepatentsonline.com/7612088.html</link>
<description><![CDATA[The application relates to novel heterocyclic compounds of the general formula (I) in which R, R 1 , R 2 , W, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Dosage forms having prolonged active ingredient release]]></title>
<link>http://www.freepatentsonline.com/7611729.html</link>
<description><![CDATA[The present invention relates to prolonged-release oral dosage forms of 4-phenylbutyric acid salts, such as sodium 4-phenylbutyrate. The prolonged release oral dosage forms are preferably tablets. The prolonged release is achieved by formulating 4-phenylbutyric acid with a delaying matrix material, such as hydroxypropylmethyl cellulose. The prolonged release oral dosage forms of the present invention may be administered once or twice a day to a patient suffering from a disease such as cancer or a urea cycle disorder.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof]]></title>
<link>http://www.freepatentsonline.com/7612090.html</link>
<description><![CDATA[Provided herein are compounds of the formula (I):  
 
wherein R 1 -R 8  are as described herein, R 4  being aryl or heteroaryl Such compounds are particularly useful in the treatment of a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Use of extracts from <i>Pelargonium </i>species]]></title>
<link>http://www.freepatentsonline.com/7611734.html</link>
<description><![CDATA[The use of extracts from  Pelargonium  species or plant parts thereof, particularly from  P. sidoides  and  P. reniforme  for the prophylaxis or treatment of disease-related behavioral changes, the chronic or post-viral asthenia syndrome and/or stress-induced chronic pathological conditions as well as pharmaceutical preparations containing these extracts are described.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Caspase inhibitors and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7612091.html</link>
<description><![CDATA[The present invention provides a compound of formula I:  
 
wherein:
 
     X is —OR 1  or —N(R 5 ) 2 , Y is halo, trifluorophenoxy, or tetrafluorophenoxy; R 1  is:
         C 1-6  straight chained or branched alkyl, alkenyl, or alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with optionally substituted aryl, CF 3 , Cl, F, OMe, OEt, OCF 3 , CN, or NMe 2 ; C 1-6  cycloalkyl, wherein 1-2 carbon atoms in the cycloalkyl is optionally replaced with —O— or —NR 5 —; 
         R 2  is C 1-6  straight chained or branched alkyl; R 3  is hydrogen, halo, OCF 3 , CN, or CF 3 ; R 4  is hydrogen, halo, OCF 3 , CN, or CF 3 ; and each R 5  is independently H, C 1-6  straight chained or branched alkyl, aryl, —O—C 1-6  straight chained or branched alkyl, or —O-aryl. 
     
 The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated disease, particularly in the central nervous system.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-αα-dimethyl-benzeneacetic acid]]></title>
<link>http://www.freepatentsonline.com/7612095.html</link>
<description><![CDATA[Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-αα-dimethyl-benzen⊖eacetic acid Crystalline form 1 of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1 -piperidinyl]ethyl]-αα-dimethyl-benzen⊖eacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method for producing bactericidal pyridine compound and bactericidal pyridine compound]]></title>
<link>http://www.freepatentsonline.com/7612097.html</link>
<description><![CDATA[Provided are novel pyridine compounds represented by the following formula (7):  
 
wherein R 1  and R 4  may be the same or different and are each a linear or branched alkyl group having 1 to 4 carbon atoms; R 2  and R 5  are hydrogen atoms, or may be the same or different and are each a halogen atom, lower alkyl group or lower alkoxy group; R 3  is a linear or branched alkyl group having 2 to 12 carbon atoms; R 6  is a linear or branched alkyl group having 1 to 18 carbon atoms; and Z is a chlorine atom, bromine atom or iodine atom or an OSO 2 R 7  group in which R 7  is a lower alkyl group or a substituted or unsubstituted phenyl group. Also provided is their production process, which can easily provide them at low cost from readily-available pyridine compounds as starting raw materials.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Pre-mixed, ready-to-use pharmaceutical compositions]]></title>
<link>http://www.freepatentsonline.com/7612102.html</link>
<description><![CDATA[Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use]]></title>
<link>http://www.freepatentsonline.com/7612104.html</link>
<description><![CDATA[The present invention comprises bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, their functional derivatives thereof as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below,  
 
wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[2-phenylthiophene derivative]]></title>
<link>http://www.freepatentsonline.com/7612108.html</link>
<description><![CDATA[The present invention relates to a 2-phenylthiophene derivative or a salt thereof, wherein the thiophene ring is substituted with a carboxyl group or the like and the benzene ring has an electron-withdrawing group such as a cyano group and an electron-donating group such as a substituted alkoxy group at the same time. Since the compound of the invention has good xanthine oxidase-inhibitory action and uric acid-lowering action and does not have a structure derived from nucleic acid, the compound has advantages of high safety and excellent effects as compared with conventional compounds and is useful as a therapeutic or preventive agent for hyperuricemia, gout, inflammatory bowel diseases, diabetic kidney diseases, diabetic retinopathy, or the like.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hydroxy tetrahydro-naphthalenylurea derivatives]]></title>
<link>http://www.freepatentsonline.com/7612113.html</link>
<description><![CDATA[This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence, inflammatory disorders such as asthma and COPD.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Hair cleansing composition]]></title>
<link>http://www.freepatentsonline.com/7612141.html</link>
<description><![CDATA[Provided is a hair cleansing composition comprising (A) an amphipathic amide lipid, (B) an anionic surfactant and (C) a silicone. The hair cleansing composition of the present invention has advantages such as protecting hair from physical or chemical stimulation and preventing split ends or hair breakage without impairing its cleansing ability and feeling upon use, and moreover, gives to hair after shampooing a pleasant feeling to the touch and moisture retention properties such as natural smoothness, moist feeling, and suppleness which healthy hair inherently possesses, and has excellent stability.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method for treating oncological diseases]]></title>
<link>http://www.freepatentsonline.com/7612032.html</link>
<description><![CDATA[A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units/day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for delivering compounds into a cell]]></title>
<link>http://www.freepatentsonline.com/7612033.html</link>
<description><![CDATA[The present invention is directed, inter alia, to a method for delivering a compound into a cell comprising administering to the cell the compound to be delivered, an organic halide, and/or a carrier. Ultrasound may also be applied, if desired.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of cell growth inhibition with agnoprotein]]></title>
<link>http://www.freepatentsonline.com/7612039.html</link>
<description><![CDATA[The growth of normal and abnormally proliferating cells can be inhibited by the introduction of agnoprotein, or biologically active fragments or derivatives of agnoprotein, into the cell in the absence of any other polyoma virus protein or viral replication.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth]]></title>
<link>http://www.freepatentsonline.com/7612041.html</link>
<description><![CDATA[In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[11—[ (Z) -3- (dimethylamino) propylidene]—6, 11-dihydro-dibenz [B,E] oxepin-2-YI ]—acetic acid]]></title>
<link>http://www.freepatentsonline.com/7612219.html</link>
<description><![CDATA[Process for the preparation of olopatadine (I), which comprises reacting a compound of formula (V) in the presence of a palladium catalyst to provide a compound of formula (VI), wherein the acid protecting group is removed to provide the compound of formula (I) and if desired, transformation into its salts.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Degradation-resistant mononucleoside phosphate compounds]]></title>
<link>http://www.freepatentsonline.com/7612047.html</link>
<description><![CDATA[The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Acyl guanidines as beta-secretase inhibitors]]></title>
<link>http://www.freepatentsonline.com/7612069.html</link>
<description><![CDATA[There is provided a series of substituted acyl guanidines of Formula (I)  
 
or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4  and R 5  as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Vinylogous acid derivatives]]></title>
<link>http://www.freepatentsonline.com/7612099.html</link>
<description><![CDATA[The invention is concerned with vinylogous acids derivatives of formula (I)  
 
wherein A and R 1  to R 6  are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit chymase and can be used as medicaments.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives]]></title>
<link>http://www.freepatentsonline.com/7612068.html</link>
<description><![CDATA[The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Aerosol formulation for inhalation comprising an anticholinergic]]></title>
<link>http://www.freepatentsonline.com/7611694.html</link>
<description><![CDATA[The present invention relates to a propellant-free, aqueous aerosol formulation for anticholinergics of formula 1  
 
wherein X −  denotes an anion.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Prokineticin 2β peptide and its use]]></title>
<link>http://www.freepatentsonline.com/7612163.html</link>
<description><![CDATA[A PK2β peptide is described, which, as an agonist of prokineticin receptor 1, is useful for treating lung and gastrointestinal diseases or disorders mediated by PKR1 activity.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods for inhibiting heregulin and treating cancer]]></title>
<link>http://www.freepatentsonline.com/7612042.html</link>
<description><![CDATA[The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Amino-propanol derivatives]]></title>
<link>http://www.freepatentsonline.com/7612238.html</link>
<description><![CDATA[Compounds of formula I  
 
wherein R 1 , R 2 , R 3 , R 4  and R 5  are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of inhibition the growth of algae]]></title>
<link>http://www.freepatentsonline.com/7612049.html</link>
<description><![CDATA[The inhibition of Chlorophyta growth in water needed to be treated can be accomplished by the addition of about 100 ppm glucosamine. The inhibition of  Microcystic aeruginosa  and  Microcystis flos-aquae  growth in water needed to be treated can be accomplished by the addition of about 10 to 50 ppm glucosamine. The addition of glucosamine to water needed to be treated, such as reservoirs, offers an environmentally safe method for inhibiting algae growth.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Substituted oxoazaheterocyclyl compounds]]></title>
<link>http://www.freepatentsonline.com/7612075.html</link>
<description><![CDATA[This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Piperazinyl-pyridine derivatives]]></title>
<link>http://www.freepatentsonline.com/7612076.html</link>
<description><![CDATA[The present invention relates to compounds of formula I  
 
wherein R 1 , R 2 , X, Y, Z and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Crystalline forms of the anti-cancer compound ZD1839]]></title>
<link>http://www.freepatentsonline.com/7612077.html</link>
<description><![CDATA[The invention concerns certain crystalline solvates and hydrates of the compound of the Formula (I) which is known inter alia by way of the code number ZD1839. In particular, the invention concerns a first solvate that occurs in the presence of methanol which is designated as Form 2 ZD1839 MeOH solvate, a second solvate that occurs in the presence of dimethyl sulphoxide which is designated as Form 3 ZD1839 DMSO solvate and a trihydrate that occurs in the presence of water which is designated Form 5 ZD1839 trihydrate. The invention further concerns processes for the preparation of these solvates and the trihydrate and for their conversion back to the compound ZD1839, pharmaceutical compositions containing them and their use in the manufacture of medicaments for use the production of an anti-proliferative effect in a warm-blooded animal such as man.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Piperidinylamino-thieno[2,3-D] pyrimidine compounds]]></title>
<link>http://www.freepatentsonline.com/7612078.html</link>
<description><![CDATA[The invention relates to 5-HT receptor modulators, particularly 5-HT 2B  antagonists. Novel piperidinylamino-thieno[2,3-d]pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Amorphous hydrous esomeprazole magnesium]]></title>
<link>http://www.freepatentsonline.com/7612098.html</link>
<description><![CDATA[A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Anthranilamides, process for the production thereof, and pest controllers containing the same]]></title>
<link>http://www.freepatentsonline.com/7612100.html</link>
<description><![CDATA[To provide a novel anthranilamide compound or its salt which is useful as a pesticide; a process for its production; and a pesticide containing such a compound as an active ingredient.  An anthranilamide compound represented by the formula (I) or its salt. In the formula, R 1  is halogen, alkyl, haloalkyl, etc.; each of R 2  and R 3  which are independent of each other, is halogen, alkyl, haloalkyl, etc.; A is alkyl substituted by Y; Y is C 3-4  cycloalkyl which may be substituted by at least one substituent selected from the group consisting of halogen, alkyl and haloalkyl; m is from 0 to 4; n is 0 or 1; and q is from 0 to 4.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof]]></title>
<link>http://www.freepatentsonline.com/7612106.html</link>
<description><![CDATA[The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor.  
 
Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Treatment of subnormal bone mineral density]]></title>
<link>http://www.freepatentsonline.com/7612034.html</link>
<description><![CDATA[A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Crystals of quinolinecarboxylic acid derivative solvate]]></title>
<link>http://www.freepatentsonline.com/7612205.html</link>
<description><![CDATA[A main object is to provide a crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid acetonitrile solvate (Compound B) which is an intermediate for producing preferentially the type III crystal of 6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl-1-piperazinyl]-4-oxo-4H-[1,3]-thiazeto[3,2-a]quinoline-3-carboxylic acid (Compound A). A crystal of Compound B can be preferentially precipitated by controlling the supersaturation concentration in crystalization using acetonitrile as a solvent. Subsequently, the type III crystal of Compound A can be produced by performing desolvation of the crystal.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Benzimidazole TRPV1 inhibitors]]></title>
<link>http://www.freepatentsonline.com/7612211.html</link>
<description><![CDATA[The invention is directed to compounds of Formula (I):  
 
to pharmaceutical compositions containing such compounds and to methods of treatment using them.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Substituted hydantoins]]></title>
<link>http://www.freepatentsonline.com/7612212.html</link>
<description><![CDATA[The present invention relates to compounds of the formula  
 
methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Sulfopyrroles]]></title>
<link>http://www.freepatentsonline.com/7612064.html</link>
<description><![CDATA[The invention relates to compounds of formula (I) wherein R 1  represents aryl, aralkyl or heteroaryl, R 2  is aryl or heteroaryl and R 3  is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I) or of pharmaceutical compositions containing same.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Tetrahydroisoquinolines as factor Xa inhibitors]]></title>
<link>http://www.freepatentsonline.com/7612089.html</link>
<description><![CDATA[The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response]]></title>
<link>http://www.freepatentsonline.com/7612162.html</link>
<description><![CDATA[The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Cross-linked glycopeptide-cephalosporin antibiotics]]></title>
<link>http://www.freepatentsonline.com/7612037.html</link>
<description><![CDATA[This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Osteoprotegerin variant proteins]]></title>
<link>http://www.freepatentsonline.com/7612169.html</link>
<description><![CDATA[The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Triazoles and methods of use]]></title>
<link>http://www.freepatentsonline.com/7612060.html</link>
<description><![CDATA[Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Tri-substituted heteroaryls and methods of making and using the same]]></title>
<link>http://www.freepatentsonline.com/7612094.html</link>
<description><![CDATA[Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.  In one embodiment, the invention features a compound of the general formula (I).]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[DB, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7612171.html</link>
<description><![CDATA[The present invention relates to identification of a receptor for a satiety factor, which is involved in body weight homeostasis. Mutations in this receptor are associated with obese phenotypes. In particular, the present invention relates to identification and characterization of the receptor for leptin, including a naturally occurring soluble form of the receptor that is expected to modulate leptin activity, in particular to agonize leptin activity. The invention further relates to the nucleic acids encoding the receptor, and to methods for using the receptor, e.g., to identify leptin analogs, therapeutically, such as in gene therapy or in soluble form as an agonist or antagonist of leptin activity, or diagnostically.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Imidazopyridazine compounds]]></title>
<link>http://www.freepatentsonline.com/7612067.html</link>
<description><![CDATA[The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Proinsulin polypeptide-oligomer conjugates]]></title>
<link>http://www.freepatentsonline.com/7611864.html</link>
<description><![CDATA[Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also described as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates are also described.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods of using cytokine zalpha11 ligand]]></title>
<link>http://www.freepatentsonline.com/7611699.html</link>
<description><![CDATA[Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Inhibitors of c-JUN N-terminal kinases (JNK)]]></title>
<link>http://www.freepatentsonline.com/7612065.html</link>
<description><![CDATA[The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Diazabicyclic aryl derivatives as cholinergy ligands]]></title>
<link>http://www.freepatentsonline.com/7612074.html</link>
<description><![CDATA[This invention relates to novel diazabicyclic aryl compounds of the formula  
 
wherein: R′ represents hydrogen or alkyl; A represents an aromatic monocyclic or bicyclic carbocyclic or heterocyclic; and is hydrogen or a subsituent as defined in the specification. The compounds are cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. The compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups]]></title>
<link>http://www.freepatentsonline.com/7612081.html</link>
<description><![CDATA[Compounds are disclosed with the general formula  
 
in which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as medicaments for the treatment of tumors and viral and parasite infections.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Sigma 2 receptor ligands and therapeutic uses therefor]]></title>
<link>http://www.freepatentsonline.com/7612085.html</link>
<description><![CDATA[A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method of producing FR901228]]></title>
<link>http://www.freepatentsonline.com/7611724.html</link>
<description><![CDATA[Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nitrogen-containing aromatic derivatives]]></title>
<link>http://www.freepatentsonline.com/7612092.html</link>
<description><![CDATA[Compounds represented by the following general formula:  
 
[wherein A g  is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X g  is —O—, —S—, etc.; Y g  is an optionally substituted C 6-14  aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T g1  is a group represented by the following general formula:
 
 
(wherein E g  is a single bond or —N(R g2 )—, R g1  and R g2  each independently represent a hydrogen atom, an optionally substituted C 1-6  alkyl group, etc. and Z g  represents a C 1-8  alkyl group, a C 3-8  alicyclic hydrocarbon group, a C 6-14  aryl group, etc.)], salts thereof or hydrates of the foregoing.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[3-arylphenyl sulfide derivative and insecticide and miticide]]></title>
<link>http://www.freepatentsonline.com/7612105.html</link>
<description><![CDATA[3-Arylphenyl sulfide derivatives represented by general formula (I):  
 
(wherein R is a C 2 -C 6  alkyl group, a C 2 -C 6  alkenyl group, a C 2 -C 6  alkynyl group or the like, B 0  to B 2  and B 3  are hydrogen atoms, halogen atoms, cyano groups, C 1 -C 4  haloalkyl groups or the like, n is 0, 1 or 2, and Ar is a phenyl ring, a pyridine ring, a thiophene ring, a pyrazole ring or the like), and insecticides and miticides containing the 3-arylphenyl sulfide derivatives as an active ingredient.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Methods of treatment using a gastric retained gabapentin dosage]]></title>
<link>http://www.freepatentsonline.com/7612112.html</link>
<description><![CDATA[A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Selective estrogen receptor modulator]]></title>
<link>http://www.freepatentsonline.com/7612114.html</link>
<description><![CDATA[The present invention provides a compound represented by the following formula (I);  
 
[wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like;  
 
formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; R a  and R b  are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R′ represents 1 to 4 independent hydrogen atoms and the like; and R″ represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma]]></title>
<link>http://www.freepatentsonline.com/7612035.html</link>
<description><![CDATA[Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Polymer-based sustained release device]]></title>
<link>http://www.freepatentsonline.com/7612176.html</link>
<description><![CDATA[This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same]]></title>
<link>http://www.freepatentsonline.com/7612208.html</link>
<description><![CDATA[A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders]]></title>
<link>http://www.freepatentsonline.com/7612079.html</link>
<description><![CDATA[The present invention relates to compounds of formula I  
 
or a pharmaceutically acceptable salt thereof wherein
 R 2  is 2-hydroxymethylpyrrolidin-1-yl, or NHCH(R 4 )CH(R 3 )OH, wherein R 3  is hydrogen or methyl and R 4  is methyl, ethyl or isopropyl; R 6  is 3-nitrophenylamino, 3,4-dimethoxybenzylamino, 3-iodobenzyl-amino, pyrid-2-yl-methylamino, pyrid-4-yl-methylamino or indan-5-amino; R 9  is isopropyl or cyclopentanyl. 
 In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and or viral disorders.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Cardiac muscle function and manipulation]]></title>
<link>http://www.freepatentsonline.com/7612164.html</link>
<description><![CDATA[This invention relates to polypeptides which affect myocardial cell differentiation and organisation of cardiac muscle contractile units, assay for identifying such polypeptides, and methods for improving cardiac function by the administration of such polypeptides to patients with heart disease. In one aspect, the invention provides a therapeutic composition comprising a peptide consisting of a fragment of human neuregulin β2 isoform containing the EGF-like domain, e.g., SEQ ID NO.:2, and a physiologically acceptable carrier, excipient or stabilizer.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Controlled release using gels in a melamine foam]]></title>
<link>http://www.freepatentsonline.com/7612029.html</link>
<description><![CDATA[A substrate comprising a nonwoven layer containing an ionically crosslinked polymer can be used to control the release of active ingredients. The substrate can be a melamine foam and contain a surfactant and an alginate polymer crosslinked with calcium.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Substituted quinobenzoxazine analogs]]></title>
<link>http://www.freepatentsonline.com/7612063.html</link>
<description><![CDATA[The present invention relates to quinobenzoxazines analogs having the general formula:  
 
and pharmaceutically acceptable salts, esters and prodrugs thereof;
 
wherein A, U, V, W, X and Z are substituents.
 The present invention also relates to methods for using such compounds.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Indole derivative having heterocycle and mono- or diazaindole derivative]]></title>
<link>http://www.freepatentsonline.com/7612070.html</link>
<description><![CDATA[There is provided a compound represented by the general formula (1):  
 
wherein Het represents an optional substituted heterocylic group A 1  and A 2  each independently represent —CH═, etc.; A 3  represents —CH 2 —, etc.; R 1  represents a 4-fluorophenyl group, etc.; R 2  represents an alkyl group; n represents 0, 1 or 2, provided that when A 1  and A 2  both are —CH═, A 3  represents —CH 2 — or —SO 2 —, which is an indole derivative or a mono- or diazaindole derivative that has COX-2 inhibitory activity and is useful as a pharmaceutical, such as an anti-inflammatory agent, or addition salts thereof with a pharmaceutically acceptable acid or base, or hydrates thereof.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nanoparticle formulations of platinum compounds]]></title>
<link>http://www.freepatentsonline.com/7611733.html</link>
<description><![CDATA[Solid Lipid Nanoparticles of platinum compounds, particularly of antitumor platinum complexes are disclosed. The Nanoparticles of the invention are obtained by a process comprising: a) preparing a first microemulsion by mixing a molten lipid, a surfactant, and optionally a co-surfactant and the platinum compound acqueous solution; b) preparing a solution by mixing a surfactant and optionally a co-surfactant in water, heating to complete solution, preferably at the same melting temperature of the lipid used in a) and adding a co-surfactant; c) dispersing the microemulsion obtained in a) into the solution obtained in b) obtaining a multiple microemulsion c); d) dispersing the microemulsion obtained in c) in aqueous medium at a temperature ranging from 0.5° C. to 4° C. obtaining a dispersion of solid lipid microspheres; e) washing with aqueous medium through ultrafiltration the obtained lipid microspheres obtained in d) and lyophilizing, optionally in the presence of a bulking agent and of a cryoprotecting agent.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Yeast genes that affect viral replication]]></title>
<link>http://www.freepatentsonline.com/7611833.html</link>
<description><![CDATA[An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1 gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 genes, MAB2 genes, MAB3 genes or OLE1 genes, homologs of these genes, related genes and combinations of these genes and homologs.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Co-stimulatory polypeptides]]></title>
<link>http://www.freepatentsonline.com/7612170.html</link>
<description><![CDATA[The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Humanised anti-mag antibody or functional fragment thereof]]></title>
<link>http://www.freepatentsonline.com/7612183.html</link>
<description><![CDATA[The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Powder composition, dispersion of this powder composition in oil and cosmetic material containing same]]></title>
<link>http://www.freepatentsonline.com/7612051.html</link>
<description><![CDATA[This invention relates to a powder composition comprising a silicone represented by the following formula (1) comprising an alcoholic hydroxyl group, and a powder, to an oil-based powder composition formed by dispersing this powder composition in an oil, and to a cosmetic material containing these materials.
 
<?in-line-formulae description="In-line Formulae" end="lead"?>R 1 a R 2 b R 3 c SiO (4−a−b−c)/2   (1)<?in-line-formulae description="In-line Formulae" end="tail"?>
 
     where, in formula (1), R 1  are identical or different organic groups selected from alkyl groups, aryl, aralkyl or fluorinated alkyl groups having 1-30 carbon atoms, R 2  is a substituent having one or more alcoholic hydroxy groups, R 3  is a group represented by the following general formula (2), 
     
  
 
      and a, b, c, d are integers satisfying the relations:
 
1.0≦a≦2.5, 0.01≦b≦1, 0.001≦c≦1, 1.5≦a+b+c≦2.6, and 0≦d≦500.
 
     
 The powder composition of this invention has little cohesion, excellent dispersibility and excellent stability over time as an oil-based powder composition. Therefore, cosmetics using these materials have excellent stability in use, and excellent stability over time.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Biglycan and related therapeutics and methods of use]]></title>
<link>http://www.freepatentsonline.com/7612038.html</link>
<description><![CDATA[The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[CC-chemokine binding tick proteins]]></title>
<link>http://www.freepatentsonline.com/7611867.html</link>
<description><![CDATA[A novel CC-chemokine binding protein is isolated from the saliva of  Rhipicephalus sanguineus . Compounds prepared in accordance with the present invention can be used as anti-inflammatory and immunomodulatory compounds and in the treatment or prevention of CC-chemokine-related diseases.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Additives and products including oligoesters]]></title>
<link>http://www.freepatentsonline.com/7611725.html</link>
<description><![CDATA[The present invention relates to oligoesters and their use or the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care products such as shampoos and conditioners. These oligoesters are particularly useful for the creation of multi-purpose additives that can impart conditioning, long substantivity and/or UV protection. Individual oligoesters and oligoester mixtures are described.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Method for treating kidney disorders]]></title>
<link>http://www.freepatentsonline.com/7612046.html</link>
<description><![CDATA[The present invention relates to a cellular therapy of renal failure, i.e. preventing, delaying, and treating acute/chronic renal failure via the use of an effective dose of a substance capable of inducing and/or enhancing Pax2 expression in a mammal for the preparation of a pharmaceutical composition for treating, preventing or delaying a renal dysfunction/failure in a mammal. Additionally, the present invention provides for a method for converting mesenchymal tissue into an epithelial tissue comprising the administration of an effective amount of a substance capable of inducing and/or enhancing Pax2 expression in mesenchymal tissue and for a method for the regeneration of renal stem cells comprising the administration of an effective amount of a substance capable of inducing and/or enhancing Pax2 expression.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nutritional supplement for osteoarthritis]]></title>
<link>http://www.freepatentsonline.com/7611732.html</link>
<description><![CDATA[The present invention relates to a method of treating osteoarthritis by administering a mineral composition in the form of a nutritional supplement, where the mineral composition may contain Smectite, Gypsum, Quartz, Feldspar, Jarosite, Kaolinite and/or Zeolite.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Eubacterial tmRNA sequences and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7611843.html</link>
<description><![CDATA[The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Nucleic acid biosensors]]></title>
<link>http://www.freepatentsonline.com/7612185.html</link>
<description><![CDATA[Sensors comprising aptazymes capable of detecting the presence and concentration of effectors, as well as methods of using such sensors, are disclosed.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Retroviral vectors for delivery of interfering RNA]]></title>
<link>http://www.freepatentsonline.com/7612195.html</link>
<description><![CDATA[Provided herein are retroviral vectors for delivering interfering RNA into cells.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Soluble highly branched glucose polymers]]></title>
<link>http://www.freepatentsonline.com/7612198.html</link>
<description><![CDATA[The invention relates to soluble highly branched glucose polymers, having a reducing sugar content of less than 1%, a level of α-1,6 glucoside bonds of between 13 and 17% and an Mw having a value of between 0.9×10 5  and 1.5×10 5  daltons, characterized in that their branched chain length distribution profile consists of 70 to 85% of DP of less than 15, of 10 to 16% of DP of between 15 and 25 and of 8 to 13% of DP greater than 25.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Polyether urethane containing allyl groups]]></title>
<link>http://www.freepatentsonline.com/7612160.html</link>
<description><![CDATA[The present invention relates to a mono- and/or polyallyl-polyether-urethane, to water-soluble or water-dispersible polymers which comprise such a polyether-urethane in copolymerized form, and to cosmetic or pharmaceutical compositions which comprise a water-soluble or water-dispersible polymer based on a mono- and/or polyallyl-polyether-urethane.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[VEGFR-3 inhibitor materials and methods]]></title>
<link>http://www.freepatentsonline.com/7611711.html</link>
<description><![CDATA[The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

<item>
<title><![CDATA[Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use]]></title>
<link>http://www.freepatentsonline.com/7612059.html</link>
<description><![CDATA[N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo 4-7 alkanes or thiazacyclo 4-7 alkanes, salts or prodrugs thereof have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by PDF inhibitors, such as treatment of bacterial infections.]]></description>
<pubDate>Tue, 03 Nov 2009 08:00:00 EST</pubDate>
</item>

</channel>
</rss>
